Neuren Pharmaceuticals Limited (ASX: NEU)
Health Care · Pharmaceuticals · AU
AU$20.20
-0.39% today · -5.6% 1Y
Neuren Pharmaceuticals Limited (ASX: NEU) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.79B and employs 9 people.
Over the last twelve months the share price has lost 5.6%, trading between 11.00 and 23.76.
Tweenvest scores Neuren Pharmaceuticals Limited across four factors: quality 75/100, value 35/100, dividend 23/100. Its strongest factor is quality.
NEU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.79B
- Revenue (TTM)
- $48.10M
- P/E
- 129.56
- EPS
- 0.16
- Dividend yield
- 1.49%
- Beta (5Y)
- 1.57
- 52-week high
- AU$23.76
- 52-week low
- AU$11.00
- Avg volume (3M)
- —
- Shares outstanding
- 126.77M
- Employees
- 9
- Next earnings
- —
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
- ISIN
- NZNEUE0001S8
- Founded
- 2001
- Listed since
- Feb 1, 2005
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Beijing Aosaikang Pharmaceutical Co., Ltd.SZSE: 002755 | $1.85B | CN¥13.34 | -1.55% |
| Structure Therapeutics Inc.NasdaqGM: GPCR | $1.82B | $24.74 | -3.15% |
| Pfizer LimitedNSEI: PFIZER | $1.80B | Rs3,808.20 | +1.55% |
| Septerna, Inc.NasdaqGM: SEPN | $1.79B | $37.96 | -1.07% |
| Zhejiang Medicine Co., Ltd.SHSE: 600216 | $1.78B | CN¥12.59 | +1.29% |
| Tsumura & Co.TSE: 4540 | $1.78B | ¥3,772.00 | +1.86% |
| PharmaBlock Sciences (Nanjing), Inc.SZSE: 300725 | $1.77B | CN¥51.01 | -7.84% |
| Nuvation Bio Inc.NYSE: NUVB | $1.76B | $4.90 | -2.00% |
Figures last refreshed Oct 11, 2026.